MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Companies

Korea Health Industry Development Institute

Korea Health Industry Development Institute
KHIDI, provides various services on technology transfer. KHIDI will license and commercialise several technologies of KHIDI's client companies via collaboration with overseas partners.

The company in detail

Profile

Professional institute leading the promotion of health industry and the technological development for building up advanced nation in the field of Bio-technology in the 21st century.

• Established the Korea Health Industry Development Institute (Feb. 6, 1999)

• Designated as an organization evaluation health industry venture companies (Small and Medium Business Administration)

• Designated as a R&D Management Institute (Health and Medical Technology Promotion Act, Act No. 6161)

• Designated as a "national health technology valuation and transfer institution" (Ministry of Health and Welfare)

• Designated as a Good Manufacturing Practices education institute (Korea Food & Drug Administration)

Major Activities of KHIDI

• Development of Policy and Strategy for Health Industry Promotion

• Promotion of Pharmaceutical and Cosmetic Industry

• Promotion of Food Industry

• Promotion of Medical Devices and Health Informatics

• Promotion of Healthcare Industry

• Quality Testing and Evaluation

• Research Planning and Evaluation Service

• Project for Commercialization

• Export Promotion and International Trade Cooperation

• Human Resources Development

Health Technology Transfer Center (HTTC-KHIDI)

• HTTC-KHIDI is a professional health technology transfer center established in Jan. 2001 as a platform for the circulation of health technology by providing various service on technology transfer, technology valuation through the domestics and overseas network. TC switches

• HTTC-KHIDI is a subsidiary of KHIDI, which is a government-supported institute under the Ministry of Health and Welfare established for the promotion of health industry and public health.

Major Activities of HTTC-KHIDI:

• Technology Transfer to other countries: Providing opportunities for overseas technology transfer, strategic partnering and investment for the excellent domestic health industries

• Support Program for the Patent Fee: Support for the patent process expense of the health technologies to promote their transfer and commercialization

• Company IR and Partnering: Provide an opportunity for biotechnology and pharmaceutical companies, research institutions, bio-clusters and investors from around the world to meet and network with potential business and technology partners, and to discuss business opportunities of mutual interests through one-on-one meetings.

Partnering strategy/interests

KHIDI will commercialise several technologies and products of KHIDI's client companies via collaboration with partners. KHIDI seeks out business partners and licenses at various stages of early drug development for client companies.

Out-licensing

Our products (KH-207 and KD-30) related to treatment of osteoarthritis focus on increase of chondrogenesis through cartilage protection as well as beneficial effects (decrease of pain and stiffness and improvement of function). We propose an alterna More
A pharmaceutical composition comprising HS024 as an active ingredient in an amount effective to protect neuronal cell and to treat or prevent human or mammal suffering from brain diseases such as brain stroke and degenerative brain diseases, together More
Porcine artificial insemination is a means to stimulate improvement in pig breeding, increase fertility, decrease breeding costs and manpower, and prevent spread of diseases. More
asthma, atopic dermatitis, allergic rhinitis More
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
Peptide molecules to specifically bind targets such as aptamer, avimer and kunitz domain have been intensively studied and developed as alternatives to antibodies. More
Cinnamic acid derivatives are good candidates to satisfy this unmet medical need More
, the composite materials of this technique can be applied to fill bone defect and replace, since they retain the excellent physical property. More
Diabetes mellitus, a metabolic disease caused by deficiency of insulin, displays a higher or lower level of glucose concentration in blood than normal range(80-120mg/dL). More
We have developed the tablet for suspension containing Amoxicillin and Potassium Clavulanate, equivalent to GSK’s Augmentin® Suspension, This product is much superior to the reference product in terms of stability during storage and don’t require stor More
Skin color is determined by concentration and distribution of melanin in the skin. A multitue of approaches and researches have been made to improve skin conditions but have finally failed to effectively improve them. More
Cytoplasmic Transduction Peptide (CTP) is one of the promising technologies possessed by Creagene. More
Dendritic cell (DC) generation and manipulation technology for the development of a cancer vaccine and rheumatoid arthritis (RA) therapeutics. Based on DC manipulating technology, Creagene is developing DC-based cancer vaccines against renal cell car More
Guided Bone Regeneration Membrane in Dental Surgery More
Direct gene amplification using AnyDirect solution gives reliable results from crude biospecimens without DNA isolation or any instrument. More
Diabetic retinopathy is one of the most common microvascular complications of diabetes, affecting nearly 50% of patients with diabetes. Diabetic retinopathy can affect almost anyone with diabetes, while an additional 5.4 million have undiagnosed dia More
In order to, to achieve the most active action of body energy, it is known that pH of water-containing blood should be maintained at an alkaline of 7.35 to 7.45. More
Pepper is a is the most widely cultivated species occupying about 31% (ca. 120,000 ha) of total vegetable-cultivating area (386,000 ha in 2000 year) and are produced on about 1,735,650 ha in 2005 in worldwide, about 60% (1,040,140 ha) of which are grown i More
Two types of vaccines for preventing and treating allergic diseases including atopic dermatitis, allergic asthma, allergic rhinitis, allergic conjunctivitis, and urticaria. More
Rotavirus is a major cause of diarrhea in infants and young children throughout the world. WHO has declared that the development of an anti-rotavirus vaccine is a project of the highest priority. More
KD501 is a partially purified extract from Scrophulariae Radix, which shows an efficacy for the treatment of strokes and degenerated neuronal disease in vivo. Elcom filed an IND application with the KFDA (The Korea Food & Drug Administration) in May More
Lotuzol is a new herbal drug composing water extract powder of Nelumbinis Semen to treat depression without sexual dysfunction, a major adverse effect in commonly used anti-depressants. More
Thus it has been pointed out that they have reduced sensitivity in the MRI diagnosis of cancer or other diseases More
This technology is related to optimal conditions for culturing stem cells and feeder cells More
The TRAP is an essential protein to infect Staphylococcus aureus in human, and the inhibitors against TRAP phosphorylation are expected to be developed as novel antibiotics of Staphylococcus aureus. More
more effective methods for preparing 2-sufonyloxy-1-phenylethanol derivatives in a high yield and a high e.e. value are now required in the industries of pharmacy More
The eventual end commercialization of our technologies are on the role of our alliances. We continuously develop our internal strengths and capabilities while reaching out to wide and solid international partnerships and collaborations. More
The genes encoding immunostimulatory molecules with anti-tumoric effects include IL-2 (interleukin-2), IL-4, IL-7, IL-12. More
Heart failure is associated with cardiac hypertropy, atheiosclerosis, myocardial infarction, valvular heart disease and hypertension. Many researches has focused on development of cardiotonics for treating heart failure. More
Apoptosis is referred to programmed cell death in a multi-cellular organism and plays a physiological role to grow a normal cell, to maintain cell homeostasis, to prevent cancer and other diseases and to protect a living body from viral or bacterial infec More
ω-conopeptide FVIA recently has developed an innovative pharmaceutical composition for preventing or treating diseases, disorders or conditions associated with N-type calcium channel activity More
Recent advances in pharmacology, molecular biology, and genetics on the serotonin system hold out the promise of the development of improved pharmacological treatment for some aspects of neurological diseases. More
Neomics has found a very promising target, AIMP2/AIMP2-DX2 for siRNA therapy application to tumoric lung cancer cells and we intend to focus the remaining resources on developing through clinical trials, the siRNA therapy as a first priority More
Ob-X is composed of herbal extracts, and reduced body and adipose tissue weight and number and size of lipid vacuoles in the liver in animal studies; reduced body weight, waist circumference and visceral fat in human studies More
Disclosed herein are a pharmaceutical formulation with high stability and dissolution, and a method for preparing the pharmaceutical formulation, More
Production process of C3 synthons by biotransformation. More
The cultured autologous squamous epithelium, which differentiates into mucociliary epithelium after in vivo grafting, are remarkably effective in airway luminal reconstruction. More
Skin care ingredients More
PWG has various business portfolios to supply SPF Micro-pig®s, CRO services for GLP studies using Micro-pig®s, development of specific disease models, and bioproducts such as artifical organs and cells. More
A series of SynLeptin peptides, particularly, SynLeptin-2 shows remarkable anti-obesity activities which were verified in animal experiments using mice and rabbits. More
We have technology to produce chiral intermediates of high quality by biotransformation More
The payload molecules to be delivered can be spontaneously encapsulated inside the TSNP. More
In this system, a miniature magnet is implanted perpendicularly in the little gap or hole incised purposely on the tympanic membrane and after the magnet is fixed through natural healing of the tympanic membrane. More
Cancer immunotherapy using dendritic cells, and iii) Camel recombinant antibodies for FoxP3, Mucl & CEA. More
the strategy targeting BLT2 overexpression or over-activation as a way for developing therapeutic composition against human cancer. More
The muscle enhancer or heart enhancer may be developed into treatments for obesity, type 2 diabetes, muscle disease, cardiac hypertrophy, or the like. And a drug or genetic treatment using TRIM72 can be used for both prevention and treatment. More
Gene-therapy product combining pCK naked DNA vector with genetically engineered Hepatocyte Growth Factor gene More

Press Releases

(5th Mar 2008) BIO KOREA 2008, South Korea's largest biotech show, is the third edition this year. More
More press releases

Contact details

Choi Keon-Seob
Senior Researcher
Technology Business Center

Contact directly

Full contact list

Head office

Korea Health Industry Development Institute
57-1 Noryangjin-Dong, Dongjak-Gu
Seoul
156-800
South Korea

Company figures

Formed: 1999
Number of employees: 154

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
Pharmalicensing Jobs
ShareVault
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us